Painful Bladder Syndrome Clinical Trial
Official title:
Diagnostic Challenges in IC (and Male CPPS)
The etiology and pathogenesis of interstitial cystitis (IC) and its related condition in men, chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) has remained elusive. This has hampered development of mechanistic treatment strategies for these common, chronic and distressing medical conditions. We believe that IC and perhaps CP/CPPS are a spectrum of complex but inter-related genetic and acquired diseases resulting from the interaction of several genes regulating immune/inflammatory and neurogenic parameters and environmental factors/circumstances or exposure, culminating in the combination of pain, frequency, urgency and sexual specific symptoms. New research has delineated the dynamic and powerful association of the immune and neurogenic system in pain activation. An immune-modulated neurogenic model of IC illuminating the action of immune derived substances and pain related substances might be important in discovering the determinants of pain, voiding dysfunction and gender specific sexual problems. This inter-related dynamic model of IC disease pathogenesis could be explored for potential avenues leading to novel diagnostic and treatment strategies. We plan to identify and evaluate the sensitivity and specificity of several novel nerve and inflammation related markers in the diagnosis and follow up of IC (and CP/CPPS). By correlating the levels of urine immune and pain related substances to disease mechanisms, severity and progression, we may be able to create a human disease specific model for diagnosis and treatment.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04313972 -
IC PaIN Trial: Interstitial Cystitis Pain Improvement With Naltrexone
|
Phase 4 | |
Recruiting |
NCT02868775 -
A Study to Determine the Role of Toll-like Receptor-4 Expression in Patients With Interstitial Cystitis/Bladder Pain Syndrome
|
N/A | |
Not yet recruiting |
NCT01410461 -
Identifying Predictors of Treatment Success in Painful Bladder Syndrome
|
N/A | |
Completed |
NCT01197261 -
OXN PR vs Placebo in Opioid-naive Subjects Suffering From Severe Pain Due to Bladder Pain Syndrome (BPS)
|
Phase 2 | |
Completed |
NCT00150488 -
URACYST® For the Treatment of GAG Deficient Interstitial Cystitis
|
N/A | |
Completed |
NCT02232282 -
Acupuncture for Female IC/PBSyndrome and Its Effect on the Urinary Microbiome: A Randomized Controlled Trial
|
N/A | |
Completed |
NCT00775281 -
Changes in Inflammatory and Contractile Protein Expression in Patients With Painful Bladder Syndrome/IC.
|
N/A | |
Completed |
NCT05223244 -
Bladder Capacity as Objective Measure of Intravesical Treatment of Newly Diagnosed IC
|
Phase 4 | |
Completed |
NCT02600715 -
Reduction of Bladder Injection Pain With Belladonna Opiate Suppository
|
Phase 4 | |
Completed |
NCT02457182 -
Mindfulness-Based Therapy for Interstitial Cystitis/Bladder Pain Syndrome
|
N/A | |
Withdrawn |
NCT03027076 -
Microbiome of Urologic Chronic Pelvic Pain Syndrome
|
N/A | |
Completed |
NCT00434343 -
Physical Therapy Trial for Pelvic Pain
|
N/A | |
Terminated |
NCT03143920 -
Hyperbaric Oxygen Therapy for Inflammatory Conditions of the Urinary Bladder
|
Early Phase 1 | |
Completed |
NCT02411110 -
A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis/Bladder Pain Syndrome
|
Phase 2 | |
Completed |
NCT00903643 -
Sensory Processing in Subjects With Painful Bladder Syndrome
|
N/A | |
Completed |
NCT00194610 -
Botox as a Treatment for Interstitial Cystitis in Women
|
Phase 4 | |
Recruiting |
NCT06299683 -
Pain Type and Interstitial Cystitis/Bladder Pain Syndrome Treatment
|
N/A | |
Terminated |
NCT04268810 -
Prospective Trial Comparing Intravesical Chondroitin Sulphate 2% and DMSO in the Treatment of PBS/Interstitial Cystitis
|
Phase 4 | |
Completed |
NCT01294878 -
Omalizumab in Interstitial Cystitis/Bladder Pain Syndrome
|
Phase 3 | |
Terminated |
NCT00451867 -
A Randomized Multicenter Double-Blind CT to Evaluate the Efficacy and Safety of Mycophenolate Mofetil . . .
|
Phase 3 |